Loading stock data…
$2.65-0.13 (-4.67%)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
C4 Therapeutics, Inc. in the Healthcare sector is trading at $2.65 with a market capitalization of $368M. Wall Street consensus targets $12.86 (7 analysts), implying a +385.2% move over the next 12 months. The stock is currently 49% below its 52-week high of $5.17, remaining 15.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.64M↑ | $6.15M↓ | $11.02M↓ | $11.23M↑ | $6.46M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.42M↑ | -$27.79M↓ | -$23.14M↑ | -$23.68M↑ | -$28.50M |
| Net Income | -$23.64M↑ | -$25.13M↓ | -$20.49M↑ | -$32.17M↓ | -$26.02M |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF...